PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung

Abstract

With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.

Keywords

• lung cancer
• squamous-cell lung cancer
• adenocarcinoma
• tumor cells
• immune cells
• pd-l1 expression